CN110996958B - 包含5,10-亚甲基-(6r)-四氢叶酸以及二羧酸的稳定的冻干物 - Google Patents

包含5,10-亚甲基-(6r)-四氢叶酸以及二羧酸的稳定的冻干物 Download PDF

Info

Publication number
CN110996958B
CN110996958B CN201880052764.1A CN201880052764A CN110996958B CN 110996958 B CN110996958 B CN 110996958B CN 201880052764 A CN201880052764 A CN 201880052764A CN 110996958 B CN110996958 B CN 110996958B
Authority
CN
China
Prior art keywords
acid
methylene
tetrahydrofolate
pharmaceutically acceptable
lyophilisate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880052764.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN110996958A (zh
Inventor
R·莫泽
V.格罗恩
T·安曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CN110996958A publication Critical patent/CN110996958A/zh
Application granted granted Critical
Publication of CN110996958B publication Critical patent/CN110996958B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/06—Oxalic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201880052764.1A 2017-08-16 2018-08-15 包含5,10-亚甲基-(6r)-四氢叶酸以及二羧酸的稳定的冻干物 Active CN110996958B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17186518 2017-08-16
EP17186518.1 2017-08-16
PCT/EP2018/072077 WO2019034673A1 (en) 2017-08-16 2018-08-15 STABLE LYOPHILISATES COMPRISING 5,10-METHYLENE- (6R) -TETRAHYDROFOLIC ACID AND DICARBOXYLIC ACID

Publications (2)

Publication Number Publication Date
CN110996958A CN110996958A (zh) 2020-04-10
CN110996958B true CN110996958B (zh) 2023-05-12

Family

ID=59699495

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880052764.1A Active CN110996958B (zh) 2017-08-16 2018-08-15 包含5,10-亚甲基-(6r)-四氢叶酸以及二羧酸的稳定的冻干物

Country Status (11)

Country Link
US (1) US11337978B2 (enExample)
EP (1) EP3668516B1 (enExample)
JP (1) JP7232815B2 (enExample)
KR (1) KR102753593B1 (enExample)
CN (1) CN110996958B (enExample)
AU (1) AU2018317789B2 (enExample)
CA (1) CA3073127A1 (enExample)
DK (1) DK3668516T3 (enExample)
ES (1) ES2902051T3 (enExample)
PT (1) PT3668516T (enExample)
WO (1) WO2019034673A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4536184A1 (en) 2022-06-08 2025-04-16 Merck Patent GmbH Concentrated solutions comprising sodium 5,10-methylene-(6r)- tetrahydrofolate
WO2023237484A1 (en) * 2022-06-08 2023-12-14 Merck Patent Gmbh Compositions comprising disodium 5,10-methylene-(6r)-tetrahydrofolate
CN119325374A (zh) * 2022-06-08 2025-01-17 默克专利股份有限公司 包含5,10-亚甲基-(6r)-四氢叶酸的稳定的冻干物
EP4536186A1 (en) * 2022-06-08 2025-04-16 Merck Patent GmbH Concentrated solutions comprising 5,10-methylene-(6r)-tetrahydrofolic acid

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0165926B1 (en) 1983-05-20 1990-10-24 Bengt Gustavsson A device for transferring a substance
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
CH682664A5 (en) 1991-10-15 1993-10-29 Eprova Ag Stable salts of 5,10-methylene tetrahydrofolate.
CH684644A5 (de) 1992-07-13 1994-11-15 Eprova Ag 5,10-Methylentetrahydrofolsäure-Cyclodextrin-Einschlussverbindungen.
US20020103126A1 (en) 1997-04-18 2002-08-01 Roche Diagnostics Gmbh Stable pharmaceutical form of administration for peptides, proteins and nucleic acids
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
CH696628A5 (de) 2002-02-26 2007-08-31 Eprova Ag Verwendung von Folaten zur Herstellung einer Zubereitung geeignet zur Vorbeugung und Behandlung von Entzündungen und entzündungsassoziierter Krankheiten, im Speziellen zur Beeinflussung der
CH697021A5 (de) 2003-06-26 2008-03-31 Merck Eprova Ag Stabile pharmazeutische Zusammensetzungen von 5, 10-Methylentetrahydrofolat.
KR20080074201A (ko) * 2005-12-02 2008-08-12 어드벤트륵스 파마슈티칼스, 인크. 5,10 메틸렌테트라히드로폴레이트의 안정한 약학 조성물
AU2012234323A1 (en) 2011-03-29 2013-10-17 Sanofi Otamixaban formulations with improved stability
JP6235779B2 (ja) 2012-03-28 2017-11-22 株式会社コーセー 葉酸含有組成物及び葉酸の安定化方法
EP2799061A1 (en) 2013-04-30 2014-11-05 Aprofol AG Stable high dose pharmaceutical composition containing folates
EP2837631A1 (en) 2013-08-14 2015-02-18 Merck & Cie New stable salt of 5,10-methylene-(6R)-tetrahydrofolic acid
CN107812195B (zh) 2014-09-04 2021-04-20 连云港金康和信药业有限公司 (6s)‐5‐甲基‐四氢叶酸钙盐的稳定药物组合物
US10059710B2 (en) * 2016-02-17 2018-08-28 Merck & Cie Stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid

Also Published As

Publication number Publication date
US11337978B2 (en) 2022-05-24
ES2902051T3 (es) 2022-03-24
AU2018317789B2 (en) 2023-06-29
EP3668516A1 (en) 2020-06-24
US20200368236A1 (en) 2020-11-26
AU2018317789A1 (en) 2020-04-02
CA3073127A1 (en) 2019-02-21
JP7232815B2 (ja) 2023-03-03
WO2019034673A1 (en) 2019-02-21
RU2020110073A3 (enExample) 2022-01-24
EP3668516B1 (en) 2021-09-22
RU2020110073A (ru) 2021-09-16
PT3668516T (pt) 2021-12-23
JP2020531415A (ja) 2020-11-05
DK3668516T3 (da) 2021-12-13
KR102753593B1 (ko) 2025-01-10
KR20200041354A (ko) 2020-04-21
CN110996958A (zh) 2020-04-10

Similar Documents

Publication Publication Date Title
CN110996958B (zh) 包含5,10-亚甲基-(6r)-四氢叶酸以及二羧酸的稳定的冻干物
EP2291375B1 (de) Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
US20240083895A1 (en) Compounds and compositions for treating conditions associated with sting activity
US20240018118A1 (en) Tricyclic compounds to degrade neosubstrates for medical therapy
JP5891234B2 (ja) １ｈ−ピロロ［２，３−ｂ］ピリジン誘導体
CN107667092B (zh) 作为fgfr4抑制剂的甲酰化n-杂环衍生物
JP2024072291A (ja) 同種抗体により駆動される慢性移植片対宿主病を処置及び予防する方法
CN105732617A (zh) 7-氮杂吲哚衍生物
JP2015503508A (ja) ＰＩ３Ｋ／ｍＴＯＲ阻害剤を使用する併用療法のための方法および組成物
CN101918404A (zh) 4-(吡咯并[2，3-c]吡啶-3-基)-嘧啶-2-胺衍生物
EP2794602A1 (de) 3-cyanaryl-1h-pyrazolo-(2,3-b-)pyridinderivate
CN102666538B (zh) 吡咯并吡啶基嘧啶-2-基胺衍生物
EP2646438A1 (de) 3-hetaryl-substituierte pyrrolo[2,3-b]pyridin-derivative als pdk1 - inhibitoren
JP2015531381A (ja) 腫瘍の処置のための７−アザインドール−２，７−ナフチリジン誘導体
RU2796570C2 (ru) Стабильные лиофилизаты, содержащие 5,10-метилен-(6r)-тетрагидрофолиевую кислоту
HK40027655A (en) Stable lyophilisates comprising 5,10-methylene-(6r)-tetrahydrofolic acid and a dicarboxylic acid
HK40027655B (en) Stable lyophilisates comprising 5,10-methylene-(6r)-tetrahydrofolic acid and a dicarboxylic acid
CN116490183A (zh) 采用olig2抑制剂的组合疗法
CN103764651B (zh) 适合治疗癌症疾病的7-氮杂吲哚衍生物
HK1140203A (en) 4-(pyrrolopyridinyl)pyrimidin-2-ylamine derivatives
HK1169118A (en) 3-([1,2,3]triazol-4-yl)-pyrrolo[2,3-b]pyridine derivatives

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40027655

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant